Kasabach-Merritt Syndrome in an Adult

Abstract

Laboratory evaluation revealed hemoglobin of 89 g/L, leukocyte count of 9.48x109/L (leukocyte differential: neutrophils 72%, lymphocytes 25%, eosinophils 2%, basophils 1%), platelet count of 6x109/L, prothrombin time of 13.4 s (control: 13 s), activated partial thromboplastin time of 32 s (control: 29 s), serum fibrinogen of 1.36 g/L, elevated fibrin degradation products, positive D-dimer, and normal liver and renal functions. Treatment options include compression therapy for hemangiomas, surgical excision of large solitary vascular lesions (whenever feasible), or ligation/embolization of feeder vessels when lesions are inaccessible for surgery. Conflict of Interest: The authors of this paper have no conflicts of interest, including specific financial interests, relationships, and/or affiliations relevant to the subject matter or materials included.

Headnote

Keywords: Hemangioma, Thrombocytopenia, Coagulopathy, Consumption

Anahtar Sözcükler: Hemanjiom, Trombositopeni, Koagülopati, Tüketim

To the Editor,

Kasabach-Merritt syndrome (KMS) is characterized by capillary hemangiomas and consumptive thrombocytopenia and coagulopathy, and may also be associated with microangiopathic hemolysis [1]. KMS is most commonly reported in infants and young children. Here we report a rare case of adult KMS in a 47-year-old woman, giving rise to severe thrombocytopenia and bleeding.

A 47-year-old woman presented with purpuric hemorrhages over her upper and lower limbs and gum bleeds for 8 days. She was found to have two large purple hemangiomas on the tongue (Figure 1A) and a few smaller cutaneous hemangiomas on the face (Figure 1B). These lesions had been present since her childhood and the tongue hemangiomas had enlarged over the past several years. Laboratory evaluation revealed hemoglobin of 89 g/L, leukocyte count of 9.48x109/L (leukocyte differential: neutrophils 72%, lymphocytes 25%, eosinophils 2%, basophils 1%), platelet count of 6x109/L, prothrombin time of 13.4 s (control: 13 s), activated partial thromboplastin time of 32 s (control: 29 s), serum fibrinogen of 1.36 g/L, elevated fibrin degradation products, positive D-dimer, and normal liver and renal functions. A peripheral blood smear showed normocytic normochromic erythrocytes and markedly reduced platelets. Bone marrow evaluation revealed normal erythropoiesis, myelopoiesis, and megakaryocytic hyperplasia. Contrastenhanced computed tomography of the chest and abdomen excluded deep-seated visceral hemangiomas. She received platelet transfusions and oral tranexamic acid for control of gum bleeds, and she was also started on oral prednisolone at 1 mg/kg/day. One month after starting the steroid treatment, the bleeding had stopped and the platelet count had improved to 152x109/L. However, the hemangiomas had remained the same. Considering the risk of traumatic bleeding, she was advised to have surgical excision of the tongue hemangiomas. However, she was unwilling to undergo surgery.

KMS is most commonly reported in infants and only a small percentage (~0.3%) of infants with hemangiomas develop KMS [1]. If not recognized and treated in time, KMS may be potentially fatal by causing disseminated intravascular coagulation and severe bleeding, and large hemangiomas can cause high-output cardiac failure and vital organ compression.

Though rare, KMS has been reported among adults as well [2,3,4,5]. The pathogenesis involves activation and consumption of platelets and clotting factors inside hemangiomas, giving rise to consumption coagulopathy and bleeding. However, no correlation has been reported between site, size, and number of hemangiomas and the development of KMS [1]. Cutaneous and visceral hemangiomas have both been implicated in KMS. Work-up in the index patient revealed probable lowgrade disseminated intravascular coagulation, but there was no evidence of microangiopathic hemolysis. Histologically, kaposiform hemangioendotheliomas and tufted angiomas are the most frequent lesions reported in KMS [1]. Treatment options include compression therapy for hemangiomas, surgical excision of large solitary vascular lesions (whenever feasible), or ligation/embolization of feeder vessels when lesions are inaccessible for surgery. Systemic steroids and interferon alfa have shown benefit when vascular lesions are extensive and not amenable to surgery or embolization.

Informed Consent: Informed consent has been obtained from the patient for publication of her clinical images.

Conflict of Interest: The authors of this paper have no conflicts of interest, including specific financial interests, relationships, and/or affiliations relevant to the subject matter or materials included.

References

References

1. Hall GW. Kasabach-Merrltt syndrome: pathogenesis and management. Br J Haematol 2001;112:851-862.

2. Aslan A, Vilsendorf AM, Kleine M, Bredt M, Bektas H. Adult Kasabach-Merritt syndrome due to hepatic giant hemangioma. Case Rep Gastroenterol 2009;3:306-312.

3. Liu X, Yang Z, Tan H, Xu L, Sun Y, Si S, Liu L, Zhou W, Huang J. Giant liver hemangioma with adult Kasabach-Merritt syndrome: case report and literature review. Medicine (Baltimore) 2017;96:e7688.

4. Wu KL, Liao CY, Chang CK, Ho SY, Tyan YS, Huang YC. A huge subcutaneous hematoma in an adult with Kasabach-Merritt syndrome. Am J Case Rep 2017;18:682-686.

5. Oak CY, Jun CH, Cho EA, Lee DH, Cho SB, Park CH, Joo YE, Kim HS, Rew JS, Choi SK. Hepatic hemangioma with Kasabach-Merritt syndrome in an adult patient. Korean J Gastroenterol 2016;67:220-223.